![MERZ [Logo]](skin_img/skin_logo-screen.gif){kind=logo}
We Care. Research for your Health.
Merz Pharmaceuticals GmbH acquires presence in United Kingdom with the takeover of Denfleet Pharma Ltd.
Frankfurt am Main, 09.06.2006
Merz Pharmaceuticals GmbH, Frankfurt am Main, has announced today the purchase of Denfleet Pharma Ltd., a UK based, privately owned pharmaceutical company. Merz intends to utilise Denfleet's expertise and strong hospital presence, particularly in the CNS area, to create a launch pad for future activities in the UK. This acquisition forms part of a Europe wide strategy for expansion.
"With its established products and out-performing sales organization, Denfleet Pharma perfectly complements Merz Pharmaceuticals' strategic corporate focus in the CNS area. It will also provide a basis for future product launches in the promising UK market," comments Dr. Martin Zügel, CEO of Merz Pharmaceuticals, on the acquisition.
"This represents another major step in expanding our European presence following the establishment of our subsidiary in Italy last year," said Dr. Jochen Huckmann, Chairman of the Board of Merz.
"Merz is an innovative and forward looking company with an exciting product pipeline and I am delighted with this development. The partnership provides a platform to grow the business in the UK and enhance our contribution to the provision of improved patient healthcare," stated Dr Henry Arnold, founder of Denfleet Pharma Ltd.
Merz Fact File
- Merz , a multinational company has three subsidiaries: Merz Pharmaceuticals, Merz Consumer Care, and Merz Dental
- Merz Pharmaceuticals products range from prescription drugs and OTC medicines to products for dentists and dental technicians.
- With 1.169 employees, Merz Pharmaceuticals generated approximately Eur 349 million in revenues in the fiscal year 2004/05.
- Headquarters in Frankfurt, Germany
- Merz concentrates research and development on drugs for neurological and psychiatric diseases such as Alzheimer's dementia, Parkinson's disease, and neuromuscular disturbances such as dystonia and spasticity
- Key products include:
- Axura® (Alzheimer's)
- PK-Merz® (Parkinson's)
- Solvex® (depression)
- Contractubex® / Mederma® (scars)
- Naftin® (fungal diseases)
- Pantogar® / Pantovigar® (hair loss)
- Pantostin® (hair loss)
- Hyal-System® (wrinkles)
- Hepa-Merz® (liver-related brain impairment)
- Lipo-Merz retard® (lipid metabolism disorders)
- Xeomin® (Blepharospasm; Cervical Dystonia)
- tetesept® (OTC drugs)
- Merz Spezial® (beauty care)
Denfleet Fact File
- Founded in 1994
- Concentrates on the licensing, marketing and distribution of speciality pharmaceutical products in the areas of neurology and psychiatry.
- Denfleet's main product, Denzapine (clozapine) is an atypical antipsychotic agent used in the treatment of schizophrenia and is particularly useful in patients who are resistant to other therapies.
- To maximise patient safety, Denfleet Pharma set up the Denfleet Clozapine Monitoring Service (DCMS), a web based monitoring service, to ensure that all patients are effectively monitored. Before treatment with Denzapine can be initiated, patients must be enrolled with the DCMS and have regular blood samples throughout.
- Employs 26 staff
- Turnover in fiscal year 2005/6 was £5.2million (Eur 8.1 million)
- Based in London and Elstree, Hertfordshire
Contact details:
Merz Pharma GmbH & Co. KGaACorporate Communications
Eckenheimer Landstraße 100
60318 Frankfurt
- Germany -
Tel.: +49/69 / 15 03 - 411
Fax: +49/69 / 15 03 - 400
E-Mail: presse@merz.de
- © 2010 Merz Pharma |
- Privacy Policy |
- Terms of Use |
- Imprint
- to top
![back to top [link]](skin_img/skin_contentSiteInfo-backToTop-arrow.gif)
Last update: 14 Mai 2007, 04:26
produced by GPM mbH
![Merz [Logo]](skin_img/base_logo-print.gif){kind=logo}
![Merz [Logo]](skin_img/base_claim-print.gif){kind=small}